Bharat Biotech Complete Enrollment of 25,800 Volunteers for Covaxin Phase-3 Trials

    0
    3

    Bharat Biotech Total Enrollment of 25,800 Volunteers for Covaxin Phase-3 Trials

    News18 News India Bharat Biotech Total Enrollment of 25,800 Volunteers for Covaxin Phase-3 Trials

    1-MIN READ

    Covaxin has been developed by Hyderabad-based Bharat Biotech. (File photo)

    Covaxin has been established by Hyderabad-based Bharat Biotech. (File picture)

    In a message posted on the company’s Twitter account, she thanked scientific trial websites, principal investigators and health workers for their support and rely on the “public- private partnership” vaccine discovery.

    • PTI Hyderabad
    • Last Upgraded: January 07, 2021, 20: 36 IST
    • FOLLOW United States ON:

    Bharat Biotech has actually completed enrollment of 25,800 volunteers for the Phase-3 trials of its COVID-19 vaccine Covaxin, Suchitra Ella, joint handling director, Bharat Biotech International Ltd stated on Thursday. In a message posted on the company’s Twitter account, she thanked scientific trial sites, primary investigators and health workers for their support and trust in the “public- private partnership” vaccine discovery.

    ” My deep gratitude to all the volunteers for reposing and expressing Pro Vaccine Public Health Voluntarism in the phase-3 clinical trials of India’s first totally native COVID-19 vaccine,” she said describing Covaxin. The Drug Controller General of India (DCGI) has recently offered Emergency situation Usage Authorisation for Covaxin.

    The Stage III human scientific trials of Covaxin began mid-November, targeted to be done in 26,000 volunteersacross India. The company had stated it is the only Phase-3 effectiveness study for a COVID-19 vaccine, and the largest efficacy trial (Phase-3) ever carried out for any vaccine in India.


    CLICK ON THIS LINK TO READ MORE

    ( the heading, this story has not been published by Essential India News staff and is released from a syndicated feed.).

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here